

Claims

- [c1] 1. A method of stimulating antibody dependent cellular cytotoxicity ("ADCC") to enhance the elimination of IgE-bearing B cells comprising:
administering to a mammal an anti-IgE antibody which binds to membrane bound IgE, but does not induce histamine release; and administering an ISO to the mammal.
- [c2] 2. The method of claim 1 wherein the ISO is a CpG containing oligonucleotide, or a modified CpG-containing oligonucleotide with an electron-withdrawing group at least at position C-5 of the cytosine in the CpG sequence.
- [c3] 3. The method of claim 1 wherein the antibody has a human IgG1 or IgG3 Fc portion, or a mouse IgG2a Fc region.
- [c4] 4. The method of claim 2 wherein the anti-IgE antibody is Hu-901, E25, E26 or E27.
- [c5] 112 2015. The method of any of claims 1 to 4, further including administering an allergen to the subject.
- [c6] 6. The method of claim 5 wherein the allergen is conjugated to the CpG-containing oligonucleotide.
- [c7] 7. The method of claim 5 wherein the mammal is a human being.
- [c8] 8. The method of claim 5 wherein the CpG-containing oligonucleotide has the formula: NDCGHN (SEQ ID NO 5), wherein N is any nucleotide, D is any nucleotide other than cytosine and H is any nucleotide other than guanine.
- [c9] 9. The method of claim 5 wherein CpG-containing oligonucleotide has one of the following sequences: AACGTTCC (SEQ ID NO 1), AACGTCG (SEQ ID NO 2), GACGTTCC (SEQ ID NO 3) or GACGTCG (SEQ ID NO 4).